FRANKFURT (Reuters) - CureVac’s experimental COVID-19 vaccine triggered an immune response in humans, the German biotech firm said on Monday, putting it on track to start mass testing this year as the race to end the pandemic heats up.
“We are very encouraged by the interim Phase I data,” Chief Executive Officer Franz-Werner Haas said in a statement.
The biotech firm is using the so-called messenger RNA (mRNA) approach, the same as Moderna as well as BioNTech and its partner Pfizer, although they started mass testing on humans in late July.
CureVac said its potential vaccine, known as CVnCoV, was generally well tolerated and trial results strongly supported the company’s plans to launch the final stage of testing involving about 30,000 participants before the end of the year.
CureVac - backed by German biotech investor Dietmar Hopp, the Gates Foundation and GlaxoSmithKline - said volunteers developed a level of neutralising antibodies on a par with people who had recovered from a serious case of COVID-19.
The pandemic, which has claimed more than 1.2 million lives globally, has triggered a scramble to develop a vaccine with about 45 experimental compounds being tested on humans.
Britain’s AstraZeneca, working with the University of Oxford, is also among the leading contenders with late-stage trial results expected this year. Their candidate is based on another virus, rather than mRNA, to deliver genetic instructions into the body for an immunisation effect.
Anthony Fauci, the top U.S. infectious diseases expert, said on Thursday that the first doses of a safe and effective coronavirus vaccine will likely become available to some high-risk Americans in late December or early January.
LOOKING FOR A PARTNER
CureVac’s hopes of offering a vaccine at much lower doses than its mRNA competitors may have been dented as it has picked the highest concentration of five dosages - from 2 to 12 micrograms per shot - for its prospective Phase III trial.
BioNTech and Pfizer have said the 30 microgram shot they opted for in their late-stage trial had previously been shown to produce antibody levels above those registered in people who had recovered from COVID-19.
Moderna, which like BioNTech expects to have the first efficacy data from its mass trial this month, is testing a 100 microgram shot that has also been shown to trigger an antibody response above that of recovered patients.
A CureVac spokesman said even at 12 micrograms its dosage was still a relatively low.
CureVac has said it was looking into a potential partnership with a major pharmaceutical company as it seeks to scale up development, production and distribution. The spokesman said on Monday that the firm was looking into various options.
The 20-year-old company, which went public on the Nasdaq exchange in August, said its Phase I study has so far enrolled more than 250 healthy individuals aged 18 to 60 years in Germany and Belgium.
It said its inoculation appears to also generate T cells against the coronavirus, another key indicator of an effective immune system arsenal, but more analysis of this was ongoing.
CureVac said side effects occurred mostly after the second injection of its two-dose regimen and included fatigue, headache, chills, muscle pain and, to a lesser extent, fever.
These conditions “resolved rapidly, usually within 24 to 48 hours”, it said.
Reporting by Ludwig Burger; Editing by David Clarke
Our Standards: The Thomson Reuters Trust Principles.